Paper Details

  1. Home
  2. Paper Details

The influence of age and gender on the pharmacokinetics of moxifloxacin.

Author: HellerA H, LettieriJ T, LiuP, SullivanJ T

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Moxifloxacin does not exhibit age- or gender-dependent pharmacokinetics. Oral doses of 200 to 400mg yield effective antibacterial concentrations on the first day of administration.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: Moxifloxacin is a new 8-methoxyfluoroquinolone with a broad antibacterial spectrum. The purpose of the present study was to determine the effects of age and gender on pharmacokinetics, surrogate pharmacodynamics, safety and tolerability of a single dose of moxifloxacin. DESIGN: This was ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2165/00003088-200140001-00002

データ提供：米国国立医学図書館（NLM）

Moxifloxacin: A Steady Hand in the Desert of Infection

The world of infectious diseases is a vast and unpredictable landscape, with numerous pathogens posing a constant threat. This study focuses on moxifloxacin, a fluoroquinolone antibiotic, and explores its pharmacokinetics in different age and gender groups. The researchers conducted a randomized, double-blind, placebo-controlled study to assess the effects of age and gender on the pharmacokinetics of moxifloxacin in healthy volunteers. The study found that moxifloxacin exhibited linear pharmacokinetics and did not show significant age- or gender-dependent variability. The authors concluded that moxifloxacin is a well-tolerated antibiotic with predictable pharmacokinetics, making it a potentially valuable tool in the treatment of various infections.

Moxifloxacin: A Reliable Ally in the Fight Against Infection

The study reveals that moxifloxacin exhibits predictable pharmacokinetics, with no significant influence from age or gender. This is a key finding because it suggests that moxifloxacin can be effectively administered to a wide range of patients without significant adjustments in dosage. This predictability, like a reliable camel navigating a familiar desert route, makes moxifloxacin a valuable tool in the fight against infection.

Navigating the Desert of Infection: A Steady Course

This research provides valuable insights into the pharmacokinetics of moxifloxacin, an important antibiotic used to treat various infections. The study's findings suggest that moxifloxacin is a well-tolerated medication with predictable pharmacokinetics, making it a reliable choice for treating infections in patients of different ages and genders. Like a steady camel carrying precious water through a vast desert, moxifloxacin can help navigate the challenges of infection and restore health.

Dr.Camel's Conclusion

This research provides valuable insights into the pharmacokinetics of moxifloxacin, a fluoroquinolone antibiotic used to treat various infections. The study found that moxifloxacin exhibits predictable pharmacokinetics and is well-tolerated, making it a valuable tool in the fight against infection. Like a reliable camel navigating a challenging desert landscape, moxifloxacin can be a steady and effective ally in the treatment of infectious diseases.

Date :
  1. Date Completed 2001-09-20
  2. Date Revised 2018-11-30
Further Info :

Pubmed ID

11352437

DOI: Digital Object Identifier

10.2165/00003088-200140001-00002

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.